Biopol Chemicals IPO 2026: Subscription Status, GMP, Price Band & Key Dates

The Biopol Chemicals IPO 2026 opened on 📅 6 February 2026 as one of the latest offerings in the SME segment, drawing attention from investors seeking exposure to the specialty chemicals sector. The IPO was structured to raise approximately ₹31.26 crore through a 100% fresh issue of up to 28,94,400 equity shares, each carrying a face value of ₹10. The subscription window remained open until 📅 10 February 2026 on the NSE SME platform.

Investors interested in this issue were able to apply within the price band of ₹102 to ₹108 per share, making this a relatively affordable entry point for retail participants, especially considering the SME nature of the IPO. The lot size was set at 1,200 shares, meaning that a minimum investment at the upper price band would require around ₹2,59,200 from individual investors.

Subscription trends in the Biopol Chemicals IPO reflected moderate interest in the issue. Reports from subscription tracking platforms indicated subdued bidding, with overall subscription figures showing slow uptake compared to other SME IPOs. For example, the retail category was subscribed at approximately 0.45 times, resulting in an overall subscription rate of about 0.29 times at certain intervals during the bidding period. These figures suggested that while the IPO had garnered participation, demand was not overwhelming by mid‑subscription levels.

Another key aspect for investors tracking the primary market was the Grey Market Premium (GMP), an unofficial indicator of expected listing performance. For the Biopol Chemicals IPO, GMP remained neutral at around ₹0, indicating that the unlisted shares were not trading at any premium over the issue price in unofficial markets. A flat or zero GMP generally implies that market participants expect the listing to be at or near the issue price, though it does not guarantee actual performance on listing day.

The company behind the IPO, Biopol Chemicals Limited, operates in the manufacturing and distribution of a range of speciality chemicals, including silicones, emulsifiers, biochemicals and polyelectrolytes. These products are supplied primarily to industrial clients across sectors such as agrochemicals, dyes, pharmaceuticals and water treatment chemicals. With operations spanning key regions including Gujarat and West Bengal, Biopol has positioned itself as a B2B supplier with diversified product offerings and regional reach.

According to the IPO timetable, the basis of allotment for investors was scheduled to be finalised on 📅 11 February 2026, immediately after the close of the subscription period. Successful applicants were expected to see their allotted shares credited to their Demat accounts on 📅 12 February 2026, while refunds for unsuccessful bids were also anticipated around the same date. The next milestone for investors was the **expected listing on 📅 13 February 2026 on the NSE SME platform, marking the first opportunity for the shares to begin trading publicly.

Despite tepid subscription figures and a flat GMP, the Biopol Chemicals IPO offered investors a chance to participate in a growing SME focused on specialty chemicals with an established manufacturing footprint and a diversified client base. The performance of the listing and subsequent market sentiment would provide clearer signals on investor confidence once trading commenced.